BioInvent International AB (publ) (0H22.IL)

26.67 +1.52 (+6.06%) At close: 05:15PM BST

BioInvent International AB (publ)

The Gamma Building
Ideongatan 1
Lund 223 70
Sweden
46 4 62 86 85 50
https://www.bioinvent.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 103

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Martin Welschof Ph.D.	Pres & CEO	5.06M	N/A	1961
Mr. Stefan Ericsson M.B.A.	Chief Financial Officer	N/A	N/A	1963
Ms. Marie Moores M.Sc., R.G.N.	Chief Operating Officer	N/A	N/A	N/A
Mr. Kristoffer Rudenholm Hansson	Sr. VP of Technical Operations	N/A	N/A	1974
Mr. Björn Frendéus	Chief Scientific Officer	N/A	N/A	1973
Ms. Cecilia Hofvander	Sr. Director of Investor Relations	N/A	N/A	1967
Dr. Andres McAllister	Chief Medical Officer	N/A	N/A	1956
Ms. Ingrid Teige	Head of Preclinical Research	N/A	N/A	N/A
Ms. Sylvie Ryckebusch	Chief Bus. Officer	N/A	N/A	N/A
Dr. Ingunn Munch Lindvig	Sr. VP of Regulatory Affairs	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in SEK.

Description

BioInvent International AB (publ), a clinical-stage company, discovers, researches, and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally. Its drug candidate is BI-1206 for the treatment of non-Hodgkin lymphoma and solid tumors. The company also develops tumor associated myeloid cells; cancer-associated regulatory T cells, which modulate the immune system; BT-001 for solid tumors; and BI-1808 and BI-1910, which are anti-TNFR2 antibodies for the treatment of solid tumors and cutaneous T-cell lymphoma. It has a partnership and collaboration with Transgene to co-develop BT-001 multi-functional oncolytic viruses for treatment of solid tumors; and collaboration and supply agreement with Merck to evaluate BT-001 in combination with Keytruda, and in BI-1808. BioInvent International AB (publ) was incorporated in 1996 and is based in Lund, Sweden.

Corporate governance

BioInvent International AB (publ)’s ISS governance QualityScore as of 1 October 2023 is 5. The pillar scores are Audit: 9; Board: 2; Shareholder rights: 1; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.